Zacks Investment Ideas feature highlights: Deckers Brands, Nike, On Holdings and Align Technology

Zacks highlights Deckers (DECK) and Align Technology (ALGN) as beaten-down S&P 500 opportunities with significant upside. DECK is ~53% below its Jan‑2025 highs (roughly $224 → ~$104), trades at ~15.4x forward 12‑month EPS, holds $1.4B cash, zero debt, and averaged 19% revenue and 32% GAAP EPS growth FY21–FY25 with projected revenue growth of 8% in FY26 and EPS growth of 1% in FY26 (Zacks Rank #2). ALGN is ~80% below its 2021 peak, trades near 18x forward earnings (about a 34% discount to its 15‑year median), has $1.0B cash and no debt, reported Q3 clear‑aligner volume +4.9% YoY (teens +8.3% YoY, kids +14.7% sequential), and is forecast to grow adjusted EPS >9% in 2025 and 7% in 2026; both names are presented as mean‑reversion/turnaround trades supported by solid balance sheets and improving technicals.

Analysis

Market structure: The winners are niche performance footwear (Deckers DECK, On ONON/HOKA) and recovering elective medical tech (Align ALGN) as consumers rotate from mega-cap AI into beaten-down cyclicals; losers are legacy broad-sports brands (Nike NKE) and discretionary categories sensitive to tariff/inflation shocks. Pricing power shifts toward D2C and differentiated product categories (HOKA, Clear Aligner) where mix improvement can drive 200–500bp margin expansion over 12–24 months. Cross-asset: a sustained rotation would depress high-growth tech multiples, modestly steepen credit spreads for discretionary retailers with weak balance sheets, and lift implied vols in consumer/healthcare names while supporting USD-sensitive revenue headwinds for exporters.

Risk assessment: Tail risks include a US consumer recession (GDP contraction >1% annualized within 12 months), regulatory action tightening dentist/aligner direct-to-consumer channels, or renewed tariff escalation hitting COGS. Time buckets: immediate (days–weeks) volatility around Q4/FY26 guidance; short-term (3–9 months) depends on holiday sell-through and clinic volumes; long-term (12–36 months) is execution on international expansion and M&A. Hidden dependencies: DECK’s upside is concentrated in HOKA momentum and D2C cadence; ALGN recovery needs sustained clinician adoption and ASP stability. Key catalysts: upcoming earnings/guidance, US teen/kids volume trends, and inventory-to-sales reads over next 2 quarters.

Trade implications: Establish a 2–3% long in DECK at current levels (~$104) targeting ~100–115% to prior highs (~$224) over 12–24 months; set a tactical stop at ~25% below entry (~$78) or on a break of the 2023 breakout support. Take a smaller 1–2% asymmetric exposure to ALGN via 12–18 month LEAP calls or a 1:1 call-debit spread (buy 20–30% OTM, sell nearer OTM) to limit premium, target 50–100% on earnings normalization by 2028. Implement a pair trade: long DECK / short NKE equal notional (6–12 month horizon) to express share-shift; reduce high-multiple AI exposure by 5–10% to fund these positions.

Contrarian angles: Consensus underweights execution risk — DECK’s valuation already assumes margin reacceleration (15.4x forward) and ALGN assumes clinic recovery to fuel 7–9% EPS CAGR; both can disappoint if mix or pricing erodes. The market may be overdiscounting Nike’s durability; shorting NKE vs DECK requires monitoring NKE’s pricing actions and inventory-to-sales — if NKE executes price/mix moves, the pair could underperform. Historical parallels: post-peak winners (Covid-era booms) often mean‑revert 18–36 months then resume growth if balance sheets hold; scale positions only after two confirming quarterly beats or a durable break above relevant moving averages.

Key Decisions for Investors

• Establish a 2–3% long position in DECK (~$104) funded by trimming 5–10% of high-multiple AI exposure; target prior highs (~+100–115%) over 12–24 months, stop-loss at ~25% below entry (~$78) or on confirmed break below 2023 breakout support.
• Allocate 1–2% risk to ALGN via 12–18 month LEAP calls or a debit call spread (buy 20–30% OTM, sell nearer-term OTM) to limit premium; objective: 50–100% upside on clinic/volume normalization by 2028; exit or hedge if clear aligner volumes roll negative for two consecutive quarters.
• Implement a 1:1 pair trade long DECK / short NKE (equal notional, 6–12 month horizon) to express footwear share-shift; rebalance if NKE posts sustained market-share gains or DECK misses two consecutive quarters of guidance.
• Rotate portfolio: overweight consumer discretionary footwear (DECK, ONON) and selective med-tech (ALGN) by +3–5% net for 6–18 months while reducing high-valuation AI/large-cap growth exposure by 5–10%; re-assess after next two earnings cycles (60–120 days).